1Elevan Biopharmaceuticals, Inc.
BusinessSupport
Compounding safety and access
Add specific peptides to 503a list
Patient access and affordability
Table of contents
The document's own metadata, straight from the source system.
What the public is saying — stance, who's commenting, and the issues they raise.
Breakdown by commenter type.
Weekly arrivals, stacked by stance.
How each type splits across stance.
The docket's canonical issues. Select one to browse its comments.
Position map
Every non-silent position is backed by an excerpt from the comment.
Issues shown
Uncheck an issue to choose another.
| Organization | Compounding safety and access | Add specific peptides to 503a list | Peptide efficacy for healing | Patient access and affordability | Side effects of peptides |
|---|---|---|---|---|---|
1Elevan Biopharmaceuticals, Inc. BusinessSupport 1Elevan Biopharmaceuticals, Inc., a 503A compounding pharmacy, supports the inclusion of BPC-157, TB-500, MOTS-c, and Se | · | · | |||
Adaptogenics Inc. (operating as Human Extension Sciences) BusinessSupport Gurinder Sandhu, CEO of Adaptogenics Inc. | · | · | |||
Alpha & Omega Concierge PLLC BusinessSupport Richard Cron, an advanced practice registered nurse and founder of Alpha & Omega Concierge PLLC, argues in favor of incl | · | · | |||
American Academy of Peptide Medicine (AAPM) AdvocacySupport The American Academy of Peptide Medicine (AAPM) submits a formal request for the inclusion of seven specific peptide sub | · | · | |||
American Pharmacists Association (APhA) Trade associationOppose The American Pharmacists Association (APhA) opposes the inclusion of the nominated peptides on the 503A Bulks List at th | · | · | |||
BIOMOD Compounds LLC BusinessSupport BIOMOD Compounds LLC supports the inclusion of seven specific peptides on the Section 503A Bulk Drug Substances List, pr | · | · | · | ||
Coastline Wellness BusinessSupport Chris McKinley, Clinical Director of Coastline Wellness, supports including specific peptides (such as BPC-157 and TB-50 | · | · | |||
Collaborative for Evidence-Based Medicines (CEBM) AdvocacyOppose The Collaborative for Evidence-Based Medicines (CEBM) opposes the inclusion of the nominated peptide substances on the 5 | · | · | |||
Elysium Health, Inc. BusinessSupport Elysium Health, Inc. | · | · | |||
Foreviva Medical Clinic BusinessSupport Dr. | · | · | |||
IPEX Health BusinessSupport John Orton, CEO of IPEX Health, urges the Committee to include seven specific peptides on the 503A Bulk Drug Substances | · | · | |||
medical aesthetics and wellness clinic BusinessSupport Dr. | · | · | |||
Medisca, Inc. BusinessSupport Medisca, Inc., a global healthcare company and FDA-registered repackager, supports the inclusion of additional substance | · | · | · | · | |
Obesity Action Coalition AdvocacySupport The Obesity Action Coalition (OAC) supports the committee's efforts to ensure patient safety and product quality regardi | · | · | · | ||
Obesity Medicine Association AdvocacyOppose The Obesity Medicine Association (OMA) opposes the inclusion of MOTS-c on the section 503A Bulk Drug Substances List. | · | · | · | ||
Powers Family Pharmacy BusinessSupport Randy Powers, a compounding pharmacist at Powers Family Pharmacy, strongly supports including BPC-157 (free base and ace | · | · | |||
Texas Pharmacy Association Trade associationSupport The Texas Pharmacy Association supports adding seven nominated peptides to the Section 503A Bulk Drug Substances List fo | · | · |
2 organization-typed comments could not be identified.
Every mirrored comment — filter by stance, campaign, or issue.